Older Patients Had More Rhythm Interventions After Ablation
Older age and an exploratory vulnerability score were associated with greater rhythm-intervention burden after pulmonary vein isolation, but intervention-based outcomes reflect management choices as well as recurrence.
Evidence
Patients aged 75 or older had more recurrence-related rhythm interventions after pulmonary vein isolation than younger patients in a single-center observational study: 29.8%, compared with 20.8% at ages 50–74 and 14.2% under 50. Pulmonary vein isolation is a catheter-based treatment for atrial fibrillation, an irregular heart rhythm.
The study, published September 25, 2026, is covered in the Heart & Lungs briefing on age and vulnerability after pulmonary vein isolation. Its principal registry included 2,559 consecutive patients and recorded 580 same-center rhythm-intervention events. The endpoint was the first repeat pulmonary vein isolation or electrical cardioversion after the initial procedure. Electrical cardioversion uses an electrical shock to restore a regular heart rhythm.
After statistical adjustment, patients aged 75 or older had a hazard ratio of 1.35 versus those aged 50–74, with a 95% confidence interval of 1.12–1.64. A hazard ratio compares event rates during follow-up among people who have not yet experienced the endpoint. Here, 1.35 represents a 35% higher adjusted hazard—not a 35-percentage-point increase in the proportion needing intervention. The confidence interval expresses statistical uncertainty around the estimate.
An exploratory clinical-vulnerability measure called the Elderly Score also identified greater event burden. Older patients with scores of at least 2 had an adjusted hazard ratio of 1.85, with a 95% confidence interval of 1.45–2.35, compared with the age 50–74 reference group. This was not a comparison against lower-scoring older patients.
In a nested, actively followed 2022 cohort that assessed recurrence more broadly, the corresponding score association had an adjusted hazard ratio of 1.95, with a 95% confidence interval of 1.23–3.12.
Analysis
Interpretation: Both chronological age and the vulnerability score marked higher event burden within this one study. The score’s larger association does not demonstrate that it predicts outcomes better than age alone. It offers a hypothesis for prospective research rather than an established prediction tool.
The nested cohort adds another view within the same study, not independent confirmation. Its broader recurrence assessment also means its estimate should not be treated as a replication of an identical registry endpoint.
Limitations
The study was observational and conducted at one center. Treatment selection, ablation technique, follow-up intensity and management after recurrence were not randomized and may have changed over time.
The registry counted same-center interventions, not every return of atrial fibrillation. Frailty, other illnesses, and clinician or patient preferences could affect whether recurrence led to another ablation or cardioversion. Higher cardioversion use therefore cannot be interpreted as greater biological recurrence alone. The reported percentages should not be read as annual risks without a defined follow-up interval.
Statistical associations do not establish causation, clinical benefit or a useful decision threshold. The exploratory score still requires prospective evaluation in patients outside the original center.
What to watch
The key next test is prospective external validation: evaluating the score in a separate patient population. Confidence would increase if adding the score to age improved prediction over a fixed follow-up period, with predicted risks matching observed risks and systematically recorded rhythm recurrence measured separately from repeat ablation and cardioversion.